Document is current
Any future updates will be listed below
-
Authors
Kaplan, Chelsea M. https://orcid.org/0000-0001-9324-655X
Kelleher, Eoin https://orcid.org/0000-0003-2025-5556
Irani, Anushka https://orcid.org/0000-0002-7831-4208
Schrepf, Andrew
Clauw, Daniel J. https://orcid.org/0000-0002-8114-7818
Harte, Steven E. https://orcid.org/0000-0002-2929-8694
- License Information
-
More Information
Article History
Accepted: 16 April 2024
First Online: 16 May 2024
Competing interests
: D.J.C. has consulted for Aptinyx, Daiichi Sankyo, Intec, Lundbeck, Pfizer, Regeneron, Samumed, Teva, Theravance, Tonix, Virios and Zynerba; has received research funding from Aptinyx, Cerephex and Pfizer; and has been involved in litigation testifying against opioid manufacturers in the States of Oklahoma and Florida. S.E.H. has consulted for Aptinyx, Dana-Farber Cancer Institute, Indiana University Indianapolis, Memorial Sloan Kettering Cancer Center, University of North Carolina-Chapel Hill and Wayne State University; has received research funding from Aptinyx and Arbor Medical Innovations, LLC; and holds the following patents: EP2482716B1, US9307906B2, WO2011041683A2, CA2775775C, AU2010300372B2, US11701092B2, USD1010145S1, US20230077464A1 (pending), CN115720508A (pending), CA3177295A1 (pending) and EP4142583A1 (pending). All other authors declare no competing interests.
